Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast and Upcoming Conference Presentation
28 avr. 2016 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
08 mars 2016 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 08, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2015 Financial Results Conference Call With Webcast
24 févr. 2016 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will...
Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
19 nov. 2015 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure,...
Vital Therapies Announces Late Breaker and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Disease
18 nov. 2015 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure,...
Vital Therapies Announces Third Quarter 2015 Financial Results and Provides Corporate Update
05 nov. 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares
28 oct. 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver...
Vital Therapies Announces Pricing of Public Offering of Common Stock
22 oct. 2015 23h59 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver...
Vital Therapies Announces Proposed Public Offering of Common Stock
22 oct. 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver...
Vital Therapies Provides Corporate Update and Announces Date of Third Quarter 2015 Financial Results
16 oct. 2015 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...